Persistent negative free cash flow, with quarterly outflows often exceeding $6M, has reduced the cash balance to $5.3M as of 2025Q4, signaling a critical liquidity constraint.
| Cash from Operations | -25.89M | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M | -7.21M | -7.22M |
| Operating CF Margin % | - | -315850% | -265350% | -11926.47% | -32.26% | - | - | - |
| Operating CF Growth % | -73.41% | -19.03% | -4.7% | -467.77% | 45.77% | 8.61% | 0.25% | - |
| Net Income | -31.78M | -32.15M | -29.87M | -28.3M | -5.21M | -16.38M | -13.64M | -11.63M |
| Depreciation & Amortization | 44K | 244K | 903K | 1.02M | 968K | 895K | 658K | 477K |
| Stock-Based Compensation | 5.84M | 5.87M | 6.07M | 5.2M | 2.42M | 4.27M | 5.33M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 348K | 0 | 0 |
| Other Non-Cash Items | 3.38M | 1.81M | 917K | 5.08M | -56K | 196K | 74K | 3.85M |
| Working Capital Changes | -1.57M | -1.05M | 751K | -3.28M | -1.69M | 4.08M | 381K | 84K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -594K | -1.21M | 2.16M | -2.36M | 2.31M | 754K | -126K | 0 |
| Cash from Investing | 93K | 12.14M | -8.13M | -14.72M | -49K | 0 | -20K | -1.77M |
| Capital Expenditures | -1.99M | -1.1M | -381K | -1.02M | -49K | 0 | -20K | -1.77M |
| CapEx % of Revenue | 24862.5% | 13725% | 4762.5% | 602.94% | 0.44% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 18.87M | 9.89M | 28.51M | 44.02M | -478K | -270K | 18.15M | 7.89M |
| Debt Issued (Net) | 0 | 0 | 0 | 215K | 970K | -558K | 9.16M | 1.5M |
| Equity Issued (Net) | 328K | 9.89M | 27.82M | 39.65M | 0 | 143K | 8.99M | 6.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 18.54M | 0 | 688K | 4.16M | -1.45M | 145K | 0 | 0 |
| Net Change in Cash | -6.93M | -3.23M | -853K | 9.02M | -4.1M | -6.86M | 10.93M | -1.11M |
| Free Cash Flow | -27.88M | -26.37M | -21.61M | -21.3M | -3.62M | -6.58M | -7.22M | -8.99M |
| FCF Margin % | -348512.5% | -329575% | -270112.5% | -12529.41% | -32.71% | - | - | - |
| FCF Growth % | -22.88% | -22.01% | -1.45% | -488.4% | 45.03% | 8.86% | 19.67% | - |
| FCF per Share | -0.86 | -0.71 | -0.69 | -0.87 | -0.15 | -0.28 | -0.31 | -0.38 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.79x | 0.71x | 0.72x | 0.69x | 0.37x | 0.48x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 264K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical Trial Funding Shortfall
According to recent financial statements, GNLX consistently reports operating cash flow that tracks closely with net losses, with the OCF/NI ratio fluctuating between 0.48 and 1.04, suggesting that non-cash adjustments like stock-based compensation provide only a limited buffer against the company's ongoing, heavy operational cash burn.
The tight correlation between net income and operating cash flow indicates that the company's losses are primarily driven by actual cash expenditures rather than accounting accruals. Investors should monitor this relationship, as the lack of significant divergence suggests that the company's cash burn is highly sensitive to the pace of clinical trial spending.
As reported in quarterly filings, GNLX exhibits a persistent negative free cash flow trend, with quarterly outflows frequently exceeding $6M, which highlights the company's total dependence on external capital to fund its Phase 3 clinical trial activities in the absence of any meaningful commercial revenue generation.
The consistent negative FCF trajectory underscores the binary nature of the company's current business model, where every dollar spent is directed toward future clinical milestones. The lack of a path to self-funding suggests that the company remains entirely reliant on the capital markets to sustain its operations.
Based on the provided data, GNLX maintains a low capital intensity profile, with quarterly capital expenditures often remaining below $1M, reflecting a strategy that prioritizes clinical trial execution and R&D over the development of internal manufacturing or physical infrastructure that would require significant long-term capital investment.
The relatively low level of CapEx suggests that the company is outsourcing much of its manufacturing or utilizing existing facilities, which preserves cash for essential clinical development. However, this also implies that the company may face future scaling challenges if it must transition to commercial-grade manufacturing capacity.
Analysis of recent cash flow statements reveals significant volatility in working capital changes, with swings ranging from a $2.9M inflow in 2024Q4 to a $2.0M outflow in 2023Q4, indicating that the company's cash position is susceptible to the timing of vendor payments and clinical trial accruals.
This volatility suggests that management is actively managing its payables to preserve liquidity, which may be a necessary response to the company's limited cash reserves. Investors should interpret these fluctuations as a sign of the company's constrained liquidity environment rather than operational efficiency.
As noted in historical filings, GNLX regularly utilizes stock-based compensation, which reached $2.3M in 2025Q3, effectively acting as a non-cash expense that masks the true economic cost of talent retention while simultaneously diluting shareholders to support the company's ongoing, cash-intensive clinical development program.
While SBC is a standard tool for biotech firms to preserve cash, the reliance on it in the context of a $5.3M cash balance warrants further investigation into the company's long-term dilution strategy. The gap between reported net income and cash burn is partially bridged by these non-cash charges, which may mislead investors regarding the actual cash runway.
Quick answers to the most common questions about buying GNLX stock.
Genelux Corporation (GNLX) generated $-25.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Genelux Corporation (GNLX) reported negative free cash flow of $26.4M in 2025, indicating capital requirements exceeded cash from operations.
Genelux Corporation (GNLX) spent $1.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.